JP2001515029A5 - - Google Patents

Download PDF

Info

Publication number
JP2001515029A5
JP2001515029A5 JP2000509400A JP2000509400A JP2001515029A5 JP 2001515029 A5 JP2001515029 A5 JP 2001515029A5 JP 2000509400 A JP2000509400 A JP 2000509400A JP 2000509400 A JP2000509400 A JP 2000509400A JP 2001515029 A5 JP2001515029 A5 JP 2001515029A5
Authority
JP
Japan
Prior art keywords
dosage form
polymer
form according
soluble
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000509400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515029A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/015693 external-priority patent/WO1999008660A1/en
Publication of JP2001515029A publication Critical patent/JP2001515029A/ja
Publication of JP2001515029A5 publication Critical patent/JP2001515029A5/ja
Abandoned legal-status Critical Current

Links

JP2000509400A 1997-08-21 1998-07-29 粒状分散形態の固形医薬剤形 Abandoned JP2001515029A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5619597P 1997-08-21 1997-08-21
US60/056,195 1997-08-21
PCT/US1998/015693 WO1999008660A1 (en) 1997-08-21 1998-07-29 Solid pharmaceutical dosage forms in form of a particulate dispersion

Publications (2)

Publication Number Publication Date
JP2001515029A JP2001515029A (ja) 2001-09-18
JP2001515029A5 true JP2001515029A5 (enExample) 2006-01-05

Family

ID=22002810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000509400A Abandoned JP2001515029A (ja) 1997-08-21 1998-07-29 粒状分散形態の固形医薬剤形

Country Status (17)

Country Link
US (1) US20010048946A1 (enExample)
EP (1) EP1011640A1 (enExample)
JP (1) JP2001515029A (enExample)
KR (1) KR20010023085A (enExample)
AR (1) AR018252A1 (enExample)
AU (1) AU8600098A (enExample)
BR (1) BR9811972A (enExample)
CA (1) CA2292586C (enExample)
CO (1) CO4960652A1 (enExample)
GT (1) GT199800136A (enExample)
HN (1) HN1998000115A (enExample)
NZ (1) NZ502869A (enExample)
PA (1) PA8458101A1 (enExample)
PE (1) PE109599A1 (enExample)
SV (1) SV1998000104A (enExample)
WO (1) WO1999008660A1 (enExample)
ZA (1) ZA987551B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69222847T3 (de) * 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
ES2096097T3 (es) * 1991-08-02 1997-03-01 Wilcom Tufting Pty Ltd Procedimiento y sistema de formacion de nudos.
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
CZ20022047A3 (cs) 1999-12-23 2003-09-17 Pfizer Products Inc. Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE60143704D1 (de) * 2000-09-25 2011-02-03 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer medizinischen festen dispersion
CA2363902C (en) * 2000-12-07 2005-07-26 Warner-Lambert Company Process and system for controlled-release drug delivery
ES2333645T3 (es) 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
ES2333318T3 (es) * 2002-08-12 2010-02-19 Bend Research, Inc. Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
US8273371B2 (en) * 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
RU2331410C2 (ru) * 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1817008B1 (en) 2004-11-09 2020-04-01 Board of Regents, The University of Texas System Stabilized hme composition with small drug particles
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
BRPI0519466B8 (pt) * 2004-12-30 2021-05-25 Pf Medicament dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
FR2880274B1 (fr) * 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
BRPI0608609A2 (pt) * 2005-05-10 2010-01-19 Novartis Ag processo de extrusço para preparaÇço de composiÇÕes com compostos terapÊuticos fracamente compressÍveis
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
AU2007335191A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
CA2729596A1 (en) * 2008-07-03 2010-01-07 Novartis Ag Melt granulation process
WO2010136604A1 (en) * 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue
KR20140006879A (ko) 2011-02-17 2014-01-16 에프. 호프만-라 로슈 아게 고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법
PH12014500593A1 (en) * 2011-09-14 2019-09-02 Celgene Corp Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
DE69222847T3 (de) * 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
ES2109377T3 (es) * 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
JPH07324086A (ja) * 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung

Similar Documents

Publication Publication Date Title
JP2001515029A5 (enExample)
JP2513999B2 (ja) 口腔又は鼻腔用医薬組成物
CO4960652A1 (es) Formas de dosificacion farmaceuticas solidas
DK1169024T3 (da) Prægelatineret stivelse i en formulering med kontrolleret frigivelse
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
DK1741426T3 (da) Smelteekstruderede oralt administrerbare hydromorphonformuleringer
TW429154B (en) A controlled release formulation for poorly soluble basic drugs
TR200003788A2 (tr) Yavaş salımlı oral dozaj bileşim.
CR7661A (es) Composicion de comprimido de liberacion sostenida de pramipexol
ATE253894T1 (de) Pharmazeutische suspensionssysteme
JPH072649A (ja) 有効成分を徐放するための多層マトリックス系
EP1797873A3 (en) Compressed microparticles for dry injection
MY100721A (en) Therapeutic agent.
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
CA2352211A1 (en) Sustained release matrix systems for highly soluble drugs
AU2003238221A1 (en) Ibuprofen suspension
IT1270239B (it) Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
WO2002024203A3 (en) Controlled release formulations for oral administration
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
WO2001013898A3 (en) Pharmaceutical formulations with different release times
EE03510B1 (et) Tsisapriidi pikendatud vabastamisega ravimvorm suukaudseks manustamiseks, selle valmistamine ja kasutamine
JP2003511403A5 (enExample)
DE1223914T1 (de) Im mund zerfallende zusammensetzung mit mirtazapin
JP2003523385A5 (enExample)
CA2356306A1 (en) Sulfated phosphatidylinositols, their preparation and use